Cymbalta sales catalyst for Lilly's overall sales

Share this article:
Lilly credited increased Cymbalta sales for a 7% gain in overall sales for the 3rd Quarter, and said marketing and administrative costs were up 12%, due to increased advertising and promotion for the brand.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions